Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China

被引:6
|
作者
Nie, Jing [1 ]
Wu, Huina [1 ]
Sun, Lei [1 ]
Ding, Yanjiao [1 ]
Luan, Yepeng [2 ]
Wu, Jiyong [1 ]
机构
[1] Shandong Second Prov Gen Hosp, Dept Pharm, Jinan, Shandong, Peoples R China
[2] Qingdao Univ, Med Coll, Sch Pharm, Dept Med Chem, Qingdao, Shandong, Peoples R China
关键词
fuzuloparib; niraparib; olaparib; cost-effectiveness; maintenance treatment; ovarian cancer; BRCA1/2; mutation; THERAPY; CANCER; TRIALS;
D O I
10.3389/fphar.2022.987337
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Maintenance therapy with the poly (ADP-ribose) polymerase inhibitors (PARPis) for platinum-sensitive recurrent ovarian carcinoma (OC) have proven to be effective compared with placebo. We aimed to evaluate the cost-effectiveness (CE) of maintenance fuzuloparib compared to routine surveillance (RS), niraparib and olaparib for platinum-sensitive recurrent OC from the Chinese healthcare systems.Method: A partitioned survival model with three-state (progression-free, progressed, death) was constructed utilizing TreeAge Pro 2011 software to evaluate the economic value of fuzuloparib, niraparib and olaparib maintenance treatment for platinum-sensitive recurrent OC based on the clinical data derived from FZOCUS-2, ENGOT-OV16/NOVA and ENGOT-Ov21/SOLO2. Transition probabilities were estimated from the reported survival probabilities in those trials. Cost and health preference data were derived from the literature. The quality-adjusted life-years (QALYs) and lifetime costs were measured for this analysis. A 5 years horizon and 5%/year discount rates were used. One-way analysis, and probabilistic sensitivity analysis (PSA) were performed to explore the model uncertainties.Results: Total cost of fuzuloparib, niraparib and olaparib were $31628.10, $48183.48 and $54605.54, whereas they had an incremental cost-utility ratio of $31992.69, $32216.08 and $23359.26 per additional progression-free survival (PFS) QALYs gained compared with RS, relatively. Model showed that maintenance fuzuloparib achieved at least an 85.5% probability of CE at the threshold of $37654.50/QALY. One-way sensitivity analysis revealed that the results were sensitive to the PFS and the price of medicines.Conclusion: Fuzuloparib was less cost-effective for patients with germline BRCA1/2 mutation and platinum-sensitive recurrent OC compared to olaparib, but was superior to niraparib from the Chinese healthcare systems perspective.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Cost-effectiveness of maintenance niraparib with an individualized starting dosage compared to routine surveillance in patients with platinum-sensitive recurrent ovarian cancer in China
    Shi, Yin
    Xiao, Di
    Li, Shuishi
    Liu, Shao
    Zhang, Yu
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A74 - A76
  • [2] Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
    Zhong, Lixian
    Anh Thu Tran
    Tomasino, Taylor
    Nugent, Elizabeth
    Smith, Judith A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (12): : 1219 - 1228
  • [3] Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
    Shu, Yamin
    Liu, Yanxin
    He, Xucheng
    Ding, Yufeng
    Zhang, Qilin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [4] Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer
    Leung, John Hang
    Lang, Hui-Chu
    Wang, Shyh-Yau
    Lo, Hsueh Fang
    Chan, Agnes L. F.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (03) : 489 - 496
  • [5] Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
    Shi, Yin
    Xiao, Di
    Li, Shuishi
    Liu, Shao
    Zhang, Yu
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [6] Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer
    Cheng, Li-Jen
    Wong, Grace
    Chay, Wen-Yee
    Ngeow, Joanne
    Tan, Yongqiang
    Soon, Swee Sung
    Aziz, Mohamed Ismail Abdul
    Pearce, Fiona
    Ng, Kwong
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 441 - 448
  • [7] Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer
    Qiu, Yijin
    Zha, Jingkai
    Ma, Aixia
    Zhou, Ting
    GYNECOLOGIC ONCOLOGY, 2023, 174 : 175 - 181
  • [8] COST-EFFECTIVENESS OF NIRAPARIB AND OLAPARIB AS MAINTENANCE THERAPY FOR PATIENTS WITH PLATINUM SENSITIVE< RECURRENT OVARIAN CANCER
    Zhong, L.
    Tran, A. T.
    Tomasino, T.
    Smith, J. A.
    Nugent, E. K.
    VALUE IN HEALTH, 2018, 21 : S29 - S29
  • [9] Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
    Poveda, A.
    Lheureux, S.
    Colombo, N.
    Cibula, D.
    Lindemann, K.
    Weberpals, J.
    Bjurberg, M.
    Oaknin, A.
    Sikorska, M.
    Gonzalez-Martin, A.
    Madry, R.
    Perez, M. J. Rubio
    Ledermann, J.
    Davidson, R.
    Blakeley, C.
    Bennett, J.
    Barnicle, A.
    Skof, E.
    GYNECOLOGIC ONCOLOGY, 2022, 164 (03) : 498 - 504
  • [10] Cost-Effectiveness of BRCA1 and BRCA2 Mutation Testing to Target PARP Inhibitor Use in Platinum-Sensitive Recurrent Ovarian Cancer
    Secord, Angeles Alvarez
    Barnett, Jason Cory
    Ledermann, Jonathan A.
    Peterson, Bercedis L.
    Myers, Evan R.
    Havrilesky, Laura J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (05) : 846 - 852